Overview Dividends

(GSK) GlaxoSmithKline - Ratings and Ratios

Exchange: NYSE • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US37733W2044

Vaccines, Specialty Medicines, Oncology, Respiratory, General Medicines

GSK EPS (Earnings per Share)

EPS Growth (3Y CAGR): -50.52%
EPS Trend (3Y Correlation): -18.3%

GSK Revenue

Revenue Growth (3Y CAGR): 0.72%
Revenue Trend (3Y Correlation): 43.2%

Description: GSK GlaxoSmithKline September 26, 2025

GSK plc (NYSE:GSK) develops, manufactures, and markets vaccines, specialty medicines, and general medicines across the United Kingdom, United States, and global markets, operating through Commercial Operations and Total R&D segments.

Its specialty portfolio targets oncology (e.g., ovarian and endometrial cancers), respiratory-immunology (e.g., eosinophil-driven asthma), inflammation, and HIV-related inhaled therapies, while its vaccine suite spans shingles, RSV, seasonal influenza, HPV, and a broad range of pediatric and adult immunizations.

In 2023, GSK reported revenue of ≈ £34 billion, with a dividend yield of ≈ 5.3% and a free cash flow conversion of ≈ 70%, underscoring its cash-generating capacity despite ongoing pricing pressure in mature markets.

Key sector drivers include an aging global population that expands demand for chronic-disease treatments, heightened public-health focus on vaccine preparedness post-COVID-19, and regulatory trends toward price-cap mechanisms in Europe that compress margins for generic-competitor products.

GSK’s strategic collaboration with CureVac to develop mRNA vaccines for infectious diseases reflects a pivot toward next-generation platform technologies, a move that could diversify its pipeline and mitigate reliance on traditional protein-based vaccines.

For a deeper quantitative assessment of GSK’s valuation metrics, you may find the ValueRay platform useful.

GSK Stock Overview

Market Cap in USD	88,963m
Sub-Industry	Pharmaceuticals
IPO / Inception	1986-07-09

GSK Stock Ratings

Growth Rating	67.6%
Fundamental	77.3%
Dividend Rating	27.4%
Return 12m vs S&P 500	1.24%
Analyst Rating	2.88 of 5

GSK Dividends

Dividend Yield 12m	3.81%
Yield on Cost 5y	5.85%
Annual Growth 5y	-6.74%
Payout Consistency	90.7%
Payout Ratio	38.2%

GSK Growth Ratios

Growth Correlation 3m	92.6%
Growth Correlation 12m	82.8%
Growth Correlation 5y	53.6%
CAGR 5y	13.77%
CAGR/Max DD 3y (Calmar Ratio)	0.48
CAGR/Mean DD 3y (Pain Ratio)	1.54
Sharpe Ratio 12m	1.83
Alpha	10.88
Beta	0.294
Volatility	20.73%
Current Volume	9536k
Average Volume 20d	4551.8k
Stop Loss	41.9 (-3.1%)
Signal	-0.92

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (3.42b TTM) > 0 and > 6% of Revenue (6% = 1.90b TTM)

FCFTA 0.08 (>2.0%) and ΔFCFTA -0.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -8.55% (prev -11.39%; Δ 2.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 7.72b > Net Income 3.42b (YES >=105%, WARN >=100%)

Net Debt (-3.60b) to EBITDA (8.61b) ratio: -0.42 <= 3.0 (WARN <= 3.5)

Current Ratio 0.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (2.06b) change vs 12m ago -0.29% (target <= -2.0% for YES)

Gross Margin 71.36% (prev 72.56%; Δ -1.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.92% (prev 54.16%; Δ -0.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 8.15 (EBITDA TTM 8.61b / Interest Expense TTM 646.0m) >= 6 (WARN >= 3)

Altman Z'' 1.03

(A) -0.05 = (Total Current Assets 17.67b - Total Current Liabilities 20.38b) / Total Assets 59.26b

(B) 0.15 = Retained Earnings (Balance) 8.80b / Total Assets 59.26b

(D) 0.23 = Book Value of Equity 10.15b / Total Liabilities 44.90b

Total Rating: 1.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.31

1. Piotroski 4.50pt = -0.50

2. FCF Yield 5.82% = 2.91

3. FCF Margin 14.75% = 3.69

4. Debt/Equity 1.15 = 1.88

5. Debt/Ebitda -0.42 = 2.50

6. ROIC - WACC (= 19.50)% = 12.50

7. RoE 24.18% = 2.01

8. Rev. Trend 43.21% = 3.24

9. EPS Trend -18.33% = -0.92

What is the price of GSK shares?

As of October 25, 2025, the stock is trading at USD 43.24 with a total of 9,535,961 shares traded.
Over the past week, the price has changed by -1.53%, over one month by +7.62%, over three months by +14.35% and over the past year by +19.82%.

Is GlaxoSmithKline a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, GlaxoSmithKline (NYSE:GSK) is currently (October 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 77.31 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GSK is around 44.78 USD . This means that GSK is currently overvalued and has a potential downside of 3.56%.

Is GSK a buy, sell or hold?

GlaxoSmithKline has received a consensus analysts rating of 2.88. Therefor, it is recommend to hold GSK.

Strong Buy: 1
Buy: 0
Hold: 5
Sell: 1
Strong Sell: 1

What are the forecasts/targets for the GSK price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	42.6	-1.5%
Analysts Target Price	42.6	-1.5%
ValueRay Target Price	48.7	12.7%

GSK Fundamental Data Overview October 24, 2025

Market Cap GBP = 66.80b (88.96b USD * 0.7509 USD.GBP)
P/E Trailing = 19.9369
P/E Forward = 8.4388
P/S = 2.8125
P/B = 4.4222
P/EG = 0.3819
Beta = 0.294
Revenue TTM = 31.63b GBP
EBIT TTM = 5.27b GBP
EBITDA TTM = 8.61b GBP
Long Term Debt = 15.30b GBP (from longTermDebt, last quarter)
Short Term Debt = 2.35b GBP (from shortTermDebt, last fiscal year)
Debt = 16.99b GBP (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -3.60b GBP (from netDebt column, last quarter)
Enterprise Value = 80.19b GBP (66.80b + Debt 16.99b - CCE 3.60b)
Interest Coverage Ratio = 8.15 (Ebit TTM 5.27b / Interest Expense TTM 646.0m)
FCF Yield = 5.82% (FCF TTM 4.67b / Enterprise Value 80.19b)
FCF Margin = 14.75% (FCF TTM 4.67b / Revenue TTM 31.63b)
Net Margin = 10.82% (Net Income TTM 3.42b / Revenue TTM 31.63b)
Gross Margin = 71.36% ((Revenue TTM 31.63b - Cost of Revenue TTM 9.06b) / Revenue TTM)
Gross Margin QoQ = 72.89% (prev 74.23%)
Tobins Q-Ratio = 1.35 (Enterprise Value 80.19b / Total Assets 59.26b)
Interest Expense / Debt = 1.08% (Interest Expense 184.0m / Debt 16.99b)
Taxrate = 12.77% (241.0m / 1.89b)
NOPAT = 4.60b (EBIT 5.27b * (1 - 12.77%))
Current Ratio = 0.87 (Total Current Assets 17.67b / Total Current Liabilities 20.38b)
Debt / Equity = 1.15 (Debt 16.99b / totalStockholderEquity, last quarter 14.79b)
Debt / EBITDA = -0.42 (Net Debt -3.60b / EBITDA 8.61b)
Debt / FCF = -0.77 (Net Debt -3.60b / FCF TTM 4.67b)
Total Stockholder Equity = 14.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.78% (Net Income 3.42b / Total Assets 59.26b)
RoE = 24.18% (Net Income TTM 3.42b / Total Stockholder Equity 14.16b)
RoCE = 17.88% (EBIT 5.27b / Capital Employed (Equity 14.16b + L.T.Debt 15.30b))
RoIC = 25.35% (NOPAT 4.60b / Invested Capital 18.13b)
WACC = 5.85% (E(66.80b)/V(83.79b) * Re(7.10%) + D(16.99b)/V(83.79b) * Rd(1.08%) * (1-Tc(0.13)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -0.09%
[DCF Debug] Terminal Value 77.05% ; FCFE base≈4.69b ; Y1≈4.32b ; Y5≈3.90b
Fair Price DCF = 34.92 (DCF Value 70.18b / Shares Outstanding 2.01b; 5y FCF grow -9.75% → 3.0% )
EPS Correlation: -18.33 | EPS CAGR: -50.52% | SUE: -4.0 | # QB: 0
Revenue Correlation: 43.21 | Revenue CAGR: 0.72% | SUE: 0.08 | # QB: 0

Additional Sources for GSK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle